NASDAQ:AGIO
Agios Pharmaceuticals Stock News
$31.67
-0.140 (-0.440%)
At Close: Apr 24, 2024
Agios Pharmaceuticals, Inc. 2021 Q4 - Results - Earnings Call Presentation
02:01pm, Thursday, 24'th Feb 2022 Seeking AlphaThe Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company
01:01pm, Thursday, 24'th Feb 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Adagio Appoints COO David Hering As Interim CEO
Adagio Therapeutics, Inc., (NASDAQ: ADGI) announced th
Agios Pharmaceuticals GAAP EPS of -$1.81 misses by $0.12
12:12pm, Thursday, 24'th Feb 2022 Seeking Alpha
Agios Pharmaceuticals press release (AGIO): Q4 GAAP EPS of -$1.81 misses by $0.12.Cash, cash equivalents and marketable securities as of Dec
Agios Reports Fourth Quarter and Full Year 2021 Financial Results
12:00pm, Thursday, 24'th Feb 2022 GlobeNewswire Inc.
– Received FDA Approval of PYRUKYND® (mitapivat) for the Treatment of Hemolytic Anemia in Adults with Pyruvate Kinase (PK) Deficiency; First Approved Therapy for this Rare Blood Disorder –
Agios Pharmaceuticals Q4 2021 Earnings Preview
07:16pm, Wednesday, 23'rd Feb 2022 Seeking Alpha
Agios Pharmaceuticals (NASDAQ:AGIO) is scheduled to announce Q4 earnings results on Thursday, February 24th, before market open.The consensus EPS Estimate is -$1.57 (-11.3% Y/Y) and…
Biotech Stock Roundup: SAGE, ATRA Down on Study Updates, AGIO Drug Approval & More
05:57pm, Wednesday, 23'rd Feb 2022 Zacks Investment Research
Updates from SAGE and Atara (ATRA) are among a few key highlights from the biotech sector during the past week.
Agios Pharmaceuticals With FDA Approval Is A Buy
05:28am, Wednesday, 23'rd Feb 2022 Seeking Alpha
Agios Pharmaceuticals' pyrukynd (mitapivat) was approved by the FDA on February 17. Its platform could make AGIO much more valuable by the end of this decade.
Agios Pharmaceuticals With FDA Approval Is A Buy
05:28am, Wednesday, 23'rd Feb 2022 Seeking AlphaAgios Pharmaceuticals With FDA Approval Is A Buy
12:28am, Wednesday, 23'rd Feb 2022
Agios Pharmaceuticals With FDA Approval Is A Buy
Analyst Ratings For Agios Pharmaceuticals
06:02pm, Tuesday, 22'nd Feb 2022 Benzinga
Agios Pharmaceuticals (NASDAQ:AGIO) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
3
0
1
0
0
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
01:06pm, Sunday, 20'th Feb 2022 Benzinga
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries.
On the regulatory front, the Food and Drug A
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
01:06pm, Sunday, 20'th Feb 2022 Benzinga
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front, the Food and Drug Administration approved Agios Pharmaceuticals, Inc.''s (NASDAQ: AGIO ) mitapivat for treating pyruvate kinase deficiency, a rare, inherited metabolic disorder. Avenue Therapeutics, Inc. (NASDAQ: ATXI ) stock tumbled close to 60% after an FDA panel found that data included in the company''s new drug application for pain drug tramadol was inadequate to support approval. GlaxoSmithKline plc (NYSE: GSK ) and Sanofi (NASDAQ: SNY )- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) suffered setbacks after their respective late-stage studies of respiratory syncytial vaccine candidate in pregnant women and Dupixent as a treatment option for skin rash had to be halted. Here are the key catalysts for the unfolding week: Conferences 49th Annual Scientific and Technology Meeting of the American Auditory Society, AAS (hybrid event) Feb. 24-27, in Scottsdale, Arizona & online Multidisciplinary Head and Neck Cancers Symposium (virtual event): Feb. 24-27, in Phoenix, Arizona & online International Society of Nephrology''s World Congress of Nephrology, or WCN, 2022 (hybrid event): Feb. 24-27, in Kuala Lumpur & online PDUFA Dates The FDA has set a PDUFA date of Friday, Feb. 25, for its new drug application for Reata Pharmaceuticals, Inc.''s (NASDAQ: RETA ) Bardoxolone.
Agios (AGIO) Gets FDA Nod for Rare Anemia Drug Mitapivat
03:29pm, Friday, 18'th Feb 2022 Zacks Investment Research
Agios Pharmaceuticals' (AGIO) Pyrukynd (mitapivat) is the first disease-modifying therapy approved to treat PK deficiency, a rare, debilitating, blood disorder.
Agios stock gains as H.C. Wainwright raises target on FDA approval (NASDAQ:AGIO)
02:09pm, Friday, 18'th Feb 2022 Seeking Alpha
Agios Pharmaceuticals (AGIO) is trading ~2% higher in the pre-market on Friday as Wall Street reacts to the FDA approval for the company’s oral PK activator Pyrukynd (mitapivat) to…
The Daily Biotech Pulse: Regeneron-Sanofi Halt Late-Stage Dupixent Study, Agios Gets FDA Nod, Safety Scare For GSK's RSV Vaccine, Shockwave Jumps On Earnings
12:22pm, Friday, 18'th Feb 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours.
Stocks In Focus
Agios's Metabolic Disorder Treatment Receives FDA Approval
(NASDAQ: AGIO) said the U.S. Food and Drug